Shionogi acquires global rights to RADICAVA, boosting rare disease portfolio

Shionogi is set to acquire a newly established company from Tanabe Pharma Corporation that will hold global rights to RADICAVA ORS® and IV RADICAVA. This strategic acquisition aims to establish a strong commercial platform in rare disease and is expected to add approximately $700m in annual global sales.

The transaction, involving a lump sum payment of $2.5bn from Shionogi to Tanabe Pharma, is anticipated to close on or after April 1, 2026. The new business company will become a wholly-owned subsidiary of Shionogi Inc., and the deal is expected to be immediately accretive in FY26.

RADICAVA ORS® and IV RADICAVA are approved for the treatment of amyotrophic lateral sclerosis (ALS) and have been used to treat over 20,000 people with ALS in the U.S. This acquisition will integrate talent and business expertise in the rare disease area, supporting future launches in Shionogi’s development programs.